Astrana Health Third Quarter 2026 Earnings Call - ASTRANA HEALTH INC

Financial Performance:

• Third-quarter revenue reached a record $1.02 billion, up 7% year-over-year (YoY).
• Adjusted EBITDA hit a record $77.2 million, up 13% YoY, driven organically by margin expansion and operating efficiencies; performance was near the high end of guidance.
• Adjusted diluted earnings per share (EPS) was $0.71.
• Capitation revenue grew 8.5%, outpacing total revenue growth due to improved medical cost performance and risk-bearing cohort maturation.
• Free cash flow (FCF) for the first nine months was approximately $105 million.
• Debt repayment totaled $116 million during the first nine months, reducing net leverage to ~2.2x.
• General and Administrative (G&A) expenses declined to 6.2% of revenue, an 80 basis point improvement YoY.

Guidance and Future Outlook:

• Management expects at least mid-teens annual adjusted EBITDA growth in 2027.
• Medicare Advantage (MA) weighted average star ratings are projected to improve modestly in 2027 and stabilize in 2028; margins are expected to remain stable despite exclusion of certain diagnosis sources.
• Medicaid membership is forecast to decline 10% to 15% in 2027 due to work requirements, eligibility redeterminations, and asset limit changes.
• Exchange business membership attrition is running better than the previously assumed 30-40% decline; the segment remains ~3% of revenue.
• Full-year 2026 financial commitments remain on track, with FCF guidance intact.
• New Medicare Advantage partnerships are effective January 1, 2027, and two new technology clients are scheduled for onboarding by early 2027.

Business Segments and Product Lines:

• Total membership under management stands at approximately 1.5 million.
• Medicare Advantage membership grew at a high single-digit organic rate YoY, offsetting Medicaid and Exchange attrition.
• 82% of capitation revenue is now generated under full-risk arrangements (up from 76% in 2025); within Care Partners, this figure is 46% (up from 34%).
• Launched "Atlas," a next-generation provider-facing platform enabling real-time care prioritization and gap identification.
• Completed a tuck-in acquisition of an Independent Physician Association (IPA) in Georgia; added new clients in Connecticut (provider group) and California (hospital).
• Proprietary technology "Pathways" is scaling care management programs (e.g., annual wellness visits reaching 65% of eligible members) and disease management for high-risk conditions.

Market and Competitive Landscape:

• Astrana Health continues to grow while many competitors are reducing their Medicare Advantage footprints.
• The company's differentiated platform (Intelligence, Alignment, Delivery) creates a competitive flywheel, allowing for lower upfront investment in new markets and faster paths to profitability.
• Texas operations serve as a key success case for entering new markets with full-risk models, showing favorable medical cost trends and accelerating profitability three quarters post-transition.
• The acquisition integration of Prospect is viewed as complete, with gross provider retention above 99% and operating synergies near the high end of targets ($12-15M annually).

Risks and Challenges:

• Medicaid and Exchange membership attrition remains a headwind, with Medicaid declines expected in the 10-15% range and Exchange declines potentially steeper than historical norms.
• Commercial medical cost trends are running slightly above expectations, primarily driven by clinician-administered drug costs.
• Future regulatory changes, including potential exclusion of diagnosis sources in Medicare Advantage, could impact future margins, though management expects these to be immaterial.

Management Commentary and Tone:

• The tone is confident and optimistic, emphasizing disciplined execution, operating leverage, and the compounding effect of the technology platform.
• Management highlighted the successful transition from "GainShare" to "Global Risk" models in Texas as proof of their ability to assume greater risk responsibly.
• The acquisition of Prospect is no longer viewed as a separate integration initiative but as fully integrated into the core business.
• CEO Brandon Sim underscored the "flywheel" effect of their data-driven platform to improve outcomes and economics simultaneously.

Analyst Questions and Answers:

• Note: The provided transcript contains the opening remarks and CEO monologue but does not include the specific transcript of the Q&A session or questions asked by analysts.

Other Key Points:

• AI capabilities are being scaled to automate entire business processes, such as translating provider contract terms into claims configuration (reducing processing time from hours to minutes).
• The company is building a "repeatable clinical operating model" to standardize care across different geographies and physician networks.
• Operating expenses are expected to remain around 6.2% of revenue for the full year, with further leverage anticipated as AI capabilities mature.